
Contents

| | |
|--------------|------|
| Contributors | xi |
| Preface | xiii |

1 The Molecular Modeling Perspective in Drug Design

N. CLAUDE COHEN

| | |
|--|---|
| I. Definition of Molecular Modeling | 1 |
| II. The First Generation of Rational Approaches in Drug Design | 3 |
| III. Molecular Modeling: The Second Generation | 4 |
| A. Conceptual Frame and Methodology of Molecular Modeling | 4 |
| B. The Field Currently Covered | 4 |
| C. Importance of the “Bioactive Conformation” | 5 |
| IV. Molecular Mimicry and Structural Similarities | 6 |
| A. Molecular Mimicry | 6 |
| B. Structural Similarities and Superimposition Techniques | 7 |
| V. Rational Drug Design and Chemical Intuition | 7 |
| A. An Important Key and the Role of the Molecular Modelist | 7 |
| B. Limitations of Chemical Intuition | 9 |

| | |
|--|----|
| VI. Major Milestones and Future Perspectives | 16 |
| VII. Conclusion | 17 |
| References | 17 |

2 Molecular Graphics and Modeling: Tools of the Trade

RODERICK E. HUBBARD

| | |
|--|----|
| I. Introduction | 19 |
| II. Development of Molecular Graphics Hardware | 20 |
| III. Hardware for Graphics and Modeling | 23 |
| A. Central Servers | 25 |
| B. High Performance Graphics Systems | 28 |
| C. Personal Workstations | 29 |
| IV. Components of Molecular Graphics Hardware | 29 |
| A. Memory/Disk | 30 |
| B. Communications | 30 |
| C. Data Security | 31 |
| D. User Interaction | 31 |
| E. Organization | 31 |
| F. Visualization | 33 |
| G. Hardcopy/Publication | 38 |
| H. Standards | 39 |
| V. Software Components of a Molecular Graphics and Modeling System | 40 |
| A. User Interfaces | 40 |
| B. Constructing an Initial Model | 41 |
| C. Refining the Model | 43 |
| D. Manipulating the Model | 45 |
| E. Visualization | 46 |
| VI. Future Perspectives | 53 |
| References | 54 |

3 Molecular Modeling of Small Molecules

TAMARA GUND

| | |
|----------------------------|----|
| I. Introduction | 55 |
| A. History | 56 |
| B. Why Do Modeling? | 56 |
| C. Who Should Do Modeling? | 56 |
| D. Getting Started | 57 |

| | |
|---|----|
| II. Molecular Modeling Functions | 58 |
| A. Structure Generation or Retrieval | 58 |
| B. Structure Visualization | 59 |
| C. Conformation Generation | 60 |
| D. Deriving Bioactive Conformations | 64 |
| E. Molecule Superposition and Alignment | 64 |
| F. Deriving the Pharmacophoric Pattern | 66 |
| G. Receptor Mapping | 67 |
| H. Estimating Biological Activities | 68 |
| I. Molecular Interactions: Docking | 69 |
| J. Calculation of Molecular Properties | 70 |
| K. Energy Calculations | 71 |
| III. Examples of Small Molecule Modeling Work | 76 |
| A. Nicotinic Ligands | 76 |
| B. Sigma Ligands | 81 |
| C. Antimalarial Agents | 84 |
| References | 87 |

4 Computer-Assisted New Lead Design

AKIKO ITAI, MIHO YAMADA MIZUTANI, YOSHIHIKO NISHIBATA, AND
NUBUO TOMIOKA

| | |
|---|-----|
| I. Introduction | 93 |
| II. Basic Concepts | 95 |
| A. Molecular Recognition by Receptor and Ligand Design | 95 |
| B. Active Conformation | 95 |
| C. “Functon” | 96 |
| D. Approaches to Discover New Functons | 97 |
| E. Approaches to the Cases with Known and Unknown Receptor Structure | 98 |
| III. Docking Problem and Docking Methods | 100 |
| A. Program GREEN Grid: Three-Dimensional Description of Binding Site Environment and Energy Calculation | 101 |
| B. Automatic Docking Method | 103 |
| IV. Three-Dimensional Database Search Approaches | 109 |
| V. Automated Structure Construction Methods | 113 |
| A. Structure Construction Methods with Known Three-Dimensional Structure of the Receptor | 114 |
| B. Structure Construction in the Case of Unknown Receptor Structure | 124 |

| | |
|---|-----|
| VI. Scope and Limitations | 129 |
| A. Points for Consideration in Structure Construction Methods | 129 |
| B. Handling of X-Ray Structures of Proteins | 133 |
| C. Future Perspectives | 134 |
| References | 135 |

5 Experimental Techniques and Data Banks

JOHN P. PRIESTLE AND C. GREGORY PARIS

| | |
|---|-----|
| I. Experimental Techniques | 139 |
| A. X-Ray Crystallography | 139 |
| B. Nuclear Magnetic Resonance (NMR) | 150 |
| C. Results of Experimental Structures | 158 |
| D. Use of Experimental Structures in Protein Modeling | 165 |
| II. Three-Dimensional Structure Databases | 166 |
| A. Components of a Chemical Database | 167 |
| B. Data and Sources of Data | 172 |
| C. Queries and Sources of Queries | 180 |
| D. Search Engines | 189 |
| E. Successes of Three-Dimensional Database Searching | 194 |
| F. In Depth: The Brookhaven PDB | 195 |
| G. In Depth: The Cambridge Structural Database | 199 |
| III. IUPAC Conventions for Peptides and Nucleic Acids | 202 |
| A. Peptides | 202 |
| B. Nucleic Acids | 207 |
| Appendix | 213 |
| References | 214 |

6 Computer-Assisted Drug Discovery

PETER GUND, GERALD MAGGIORA, AND JAMES P. SNYDER

| | |
|--|-----|
| I. The Drug Development Process | 219 |
| A. Introduction | 219 |
| B. The Discovery and Development Process | 220 |
| C. New Lead Discovery Strategies | 220 |
| D. Composition of Drug Discovery Teams | 222 |

| | |
|---|-----|
| II. The Practice of Computer-Assisted Drug Discovery (CADD) | 222 |
| A. Current Practice of CADD in the Pharmaceutical Industry | 222 |
| B. Management Structures of CADD Groups | 224 |
| C. Contributions and Achievements of CADD Groups | 225 |
| D. The Case for Company Investments in CADD | 226 |
| III. Limitations to CADD Support | 227 |
| A. Inherent Limitations of CADD Support | 227 |
| B. State of Current Computational Models | 229 |
| C. Software and Hardware Constraints | 229 |
| D. Organizational Issues: The CADD Conundrum | 230 |
| IV. Proposals for Maximizing CADD Technology | 231 |
| V. Conclusions | 232 |
| References | 233 |

7 Modeling Drug-Receptor Interactions

KONRAD F. KOEHLER, SHASHIDHAR N. RAO, AND JAMES P. SNYDER

| | |
|---|-----|
| I. Receptors—Introduction and Definition | 235 |
| A. Macromolecular Targets | 235 |
| B. Sources of Structural Information | 237 |
| C. Ligand—Receptor Interaction | 240 |
| II. Receptor Fitting—X ray and Other Explicit Structures | 246 |
| A. Utility | 246 |
| B. Binding-Site Properties | 247 |
| C. Ligand Binding Predictions | 252 |
| D. Free Energy and the Elusive Entropy Factor | 263 |
| III. Receptor Mapping—Structurally Ill-Defined Biological Receptors | 273 |
| A. The Pharmacophore Concept | 273 |
| B. Practical Utility | 278 |
| C. A Case Study in New Lead Design | 279 |
| IV. Pseudoreceptors—A Bridge between Fitting and Mapping | 281 |
| A. The Philosophy | 281 |
| B. Construction of Reduced Protein Models | 281 |
| C. Structural Correlation with Experiment | 283 |
| V. Role of Solvent—Models and Limits | 284 |
| A. Aqueous and Nonaqueous Solvent Models | 284 |
| B. Small Molecule Energetics | 289 |

| | |
|---|-----|
| C. Macromolecular Conformation and Ligand Binding | 291 |
| VI. Peptidomimetic Design—Goals and Achievements | 293 |
| A. Interplay between Modeling and Bioassay | 293 |
| B. General Design Strategies | 296 |
| C. A Sampling of Disease Targets | 298 |
| D. Prospects for the Future | 313 |
| References | 315 |

8 Glossary of Terminology

| | |
|------------------|-----|
| J. P. TOLLENAERE | 337 |
| Index | 357 |